A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä
PD‐L1 and PD‐1 Expression in Thyroid Follicular Epithelial Dysplasia : Hashimoto Thyroiditis Related Atypia and Potential Papillary Carcinoma Precursor (2022)

Pakkanen, E., Kalfert, D., Ahtiainen, M., Ludvíková, M., Kuopio, T., & Kholová, I. (2022). PD‐L1 and PD‐1 Expression in Thyroid Follicular Epithelial Dysplasia : Hashimoto Thyroiditis Related Atypia and Potential Papillary Carcinoma Precursor. Apmis, 130(5), 276-283. https://doi.org/10.1111/apm.13218

JYU-tekijät tai -toimittajat

Julkaisun tiedot

Julkaisun kaikki tekijät tai toimittajat: Pakkanen, Emma; Kalfert, David; Ahtiainen, Maarit; Ludvíková, Marie; Kuopio, Teijo; Kholová, Ivana

Lehti tai sarja: Apmis

ISSN: 0903-4641

eISSN: 1600-0463

Julkaisuvuosi: 2022

Ilmestymispäivä: 02.03.2022

Volyymi: 130

Lehden numero: 5

Artikkelin sivunumerot: 276-283

Kustantaja: Wiley

Julkaisumaa: Yhdysvallat (USA)

Julkaisun kieli: englanti

DOI: https://doi.org/10.1111/apm.13218

Julkaisun avoin saatavuus: Avoimesti saatavilla

Julkaisukanavan avoin saatavuus: Osittain avoin julkaisukanava

Julkaisu on rinnakkaistallennettu (JYX): https://jyx.jyu.fi/handle/123456789/80159

Tiivistelmä

Programmed cell death ligand (PD-L1)/PD-1 expression has been studied in a variety of cancers and blockage of PD-L1/PD-1 pathway is a cornerstone of immunotherapy. We studied PD-L1/PD-1 immunohistochemical expression in 47 thyroid gland specimens in groups of 1) Hashimoto thyroiditis (HT) only, 2) HT and follicular epithelial dysplasia (FED) and 3) HT, FED and papillary thyroid carcinoma (PTC). PD-1 positivity was found in immune cells, namely in lymphocytes, macrophages, and plasma cells with mean values for lymphocytes and macrophages 9% in HT group, 4% in FED group, and 4% in PTC group. PD-L1 positivity was identified in both immune cells and in the normal epithelial cells. In the HT group, mean PD-L1 staining on immune cells was 6%, in FED group 5%, and in PTC group 7%. The mean PD-L1 staining on the epithelial cells in the inflammatory parenchyma was 11.7% in HT, 13.4% in FED and 8.3% in PTC group. The mean PD-L1 staining of FED foci was 47.2% in FED group and 33.6% in PTC group. The mean tumor proportion score (TPS) was 10.4% and the mean combined positive score (CPS) was 15.5. At the moment, PTC is not a target of immunotherapy. However, understanding the complex issue of concurrent inflammation and autoimmunity can importantly influence the cancer treatment in future.

YSO-asiasanat: kilpirauhanen; karsinoomat; syövän esiasteet; dysplasiat; immuunijärjestelmä

Vapaat asiasanat:  PD-1; PD-L1; Hashimoto thyroiditis; follicular epithelial dysplasia; thyroid gland; papillary thyroid carcinoma

Liittyvät organisaatiot

OKM-raportointi: Kyllä

Raportointivuosi: 2022

JUFO-taso: 1